NCT02197559

Brief Summary

The study hypothesizes that Drug -eluting stents are more effective in preventing restenosis than Bare-metal stents after Vertebral Artery Ostium stenting

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
168

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 21, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 22, 2014

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

October 24, 2016

Status Verified

July 1, 2014

Enrollment Period

1.4 years

First QC Date

July 21, 2014

Last Update Submit

October 21, 2016

Conditions

Keywords

Ischemic Stroke, restenosis,bare-metal stents, drug -eluting stents

Outcome Measures

Primary Outcomes (3)

  • Late loss in lumen diameter in follow-up ≥50%

    Late loss in lumen diameter in follow-up ≥50%

    1 year

  • Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs

    Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs

    30 days

  • Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs

    Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs

    12 months

Secondary Outcomes (1)

  • brain, gastrointestinal and urinary system bleeding in 12 months follow-up

    12 months

Study Arms (1)

BMS group, DES group

All the participants in this group will be performed with bare-metal stents or drug -eluting stents

Procedure: DES groupProcedure: BMS group

Interventions

DES groupPROCEDURE

all the participants in this group will be performed with drug -eluting stents

Also known as: Drug -eluting stents group
BMS group, DES group
BMS groupPROCEDURE

all the participants in this group will be performed with bare-metal stents

Also known as: Bare-metal stents group
BMS group, DES group

Eligibility Criteria

Age35 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Symptomatic status: as evidenced by TIA or non-severe stroke within the past 12 months attributed to 70% to 99% stenosis of vertebral artery ostium are eligible. Degree of stenosis: \>70% and \<99%; stenosis may be diagnosed by TCD, MRA, or CTA to qualify for angiogram performed as part of the study protocol, but must be confirmed by catheter angiography for enrollment in the trial. All the patients should be performed with PTAS beyond a duration of 3 weeks from the latest ischemic symptom onset. No fresh infarctions identified on MRI (indicated as high signals on DWI series) upon enrollment.Patient is willing and able to return for all follow-up visits required by the protocol Patient understands the purpose and requirements of the study, can make him/herself understood, and has signed informed consent.

You may qualify if:

  • \- symptomatic posterior circulation ischemia including monor stroke (mRS ≤2) or TIA result from the stenosis in the vertebral artery ostium.
  • % to 99% stenosis of vertebral artery ostium.

You may not qualify if:

  • etiology of stenotic lesions not atherosclerosis patients had undergone previos interventions on the vertebral artery ostium ipsilateral severe stenotic lesions in subclavian artery involved as well as vertebral artery ostium

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of neurosurgery, Xuanwu hospital

Beijing, 100053, China

Location

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Feng Ling, M.D.

    Xuanwu Hospital, Capital University of Medical Sciences, Beijing, China

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2014

First Posted

July 22, 2014

Study Start

January 1, 2014

Primary Completion

June 1, 2015

Study Completion

June 1, 2016

Last Updated

October 24, 2016

Record last verified: 2014-07

Locations